Nicola Ferrari

Company: Astex Pharmaceuticals

Job title: Research Associate- Translational R&D

Seminars:

Panel Discussion: Limitations of Humanised & PDX Models 1:45 pm

• How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells? • Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground? • Gaining data on persistence of cellular therapies without requiring additional miceRead more

day: Day One

The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma 11:30 am

• ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients • To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach via the integration of in…Read more

day: Day One